So for my fit younger patients without TP53 aberration, I really try to steer those patients toward a time-limited regimen at this point. They can certainly do well with covalent BTK inhibitors, but especially if they have low genetic risk disease, I think it’s beneficial to have a more intensive period of two or three drugs and then be able to have a long treatment-free interval without the need for continuous therapy...
So for my fit younger patients without TP53 aberration, I really try to steer those patients toward a time-limited regimen at this point. They can certainly do well with covalent BTK inhibitors, but especially if they have low genetic risk disease, I think it’s beneficial to have a more intensive period of two or three drugs and then be able to have a long treatment-free interval without the need for continuous therapy. You know, within the discussion of BTK plus BCL2 versus BCL2 and CD20, that’s a long and nuanced conversation for patients. Obviously, there’s something very attractive about an all-oral regimen like AV, very convenient for patients, particularly when starting, because they start with a couple of months of acalabrutinib alone, which is generally pretty straightforward, and then the venetoclax comes a couple of months in. With venetoclax and obinutuzumab, it starts with the obinutuzumab. So it can be a bit more challenging to get those initial infusions in. But then patients start on the venetoclax and they’re usually well debulked. So I think that’s also a great strategy. And so right now, we really don’t know what strategy would be better for patients, AV or VO? We have an ongoing phase three trial called MAGIC, which is directly comparing those two regimens, and we hope to see data from that soon to really better understand the optimal regimen for each patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.